These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1388022)

  • 1. Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Seeman P
    Neuropsychopharmacology; 1992 Aug; 7(1):55-7; discussion 73-5. PubMed ID: 1388022
    [No Abstract]   [Full Text] [Related]  

  • 2. PET studies of neuroreceptors in schizophrenia. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Wong DF
    Neuropsychopharmacology; 1992 Aug; 7(1):69-72; discussion 73-5. PubMed ID: 1388023
    [No Abstract]   [Full Text] [Related]  

  • 3. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride.
    Seeman P; Niznik HB; Guan HC
    Arch Gen Psychiatry; 1990 Dec; 47(12):1170-2. PubMed ID: 2244801
    [No Abstract]   [Full Text] [Related]  

  • 4. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Buchsbaum MS
    Neuropsychopharmacology; 1992 Aug; 7(1):67-8; discussion 73-5. PubMed ID: 1355970
    [No Abstract]   [Full Text] [Related]  

  • 6. Brain dopamine receptors in schizophrenia: PET problems.
    Seeman P
    Arch Gen Psychiatry; 1988 Jun; 45(6):598-600. PubMed ID: 3259865
    [No Abstract]   [Full Text] [Related]  

  • 7. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects.
    Smith GS; Dewey SL; Brodie JD; Logan J; Vitkun SA; Simkowitz P; Schloesser R; Alexoff DA; Hurley A; Cooper T; Volkow ND
    Am J Psychiatry; 1997 Apr; 154(4):490-6. PubMed ID: 9090335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET scanning in schizophrenia, a critical evaluation. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Murphy D; Rapoport SI
    Neuropsychopharmacology; 1992 Aug; 7(1):59-61; discussion 73-5. PubMed ID: 1524656
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride.
    Farde L
    Psychopharmacology (Berl); 1992; 107(1):23-9. PubMed ID: 1534178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.
    Hietala J; Syvälahti E; Vuorio K; Någren K; Lehikoinen P; Ruotsalainen U; Räkköläinen V; Lehtinen V; Wegelius U
    Arch Gen Psychiatry; 1994 Feb; 51(2):116-23. PubMed ID: 7905257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain.
    Seeman P; Guan HC; Niznik HB
    Synapse; 1989; 3(1):96-7. PubMed ID: 2521961
    [No Abstract]   [Full Text] [Related]  

  • 12. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
    Wiesel FA; Farde L; Nordström AL; Sedvall G
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):759-67. PubMed ID: 1981395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis.
    Farde L; Eriksson L; Blomquist G; Halldin C
    J Cereb Blood Flow Metab; 1989 Oct; 9(5):696-708. PubMed ID: 2528555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raclopride, a new selective ligand for the dopamine-D2 receptors.
    Hall H; Köhler C; Gawell L; Farde L; Sedvall G
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(5):559-68. PubMed ID: 2975809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D4 receptors and schizophrenia.
    Strange PG; Vile JM
    J Neurochem; 1995 Nov; 65(5):2381-3. PubMed ID: 7595530
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopamine D4 receptors elevated in schizophrenia.
    Seeman P; Guan HC; Van Tol HH
    Nature; 1993 Sep; 365(6445):441-5. PubMed ID: 8413587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping of central D2 dopamine receptors in man using [11C]raclopride: PET with anatomic standardization technique.
    Ito H; Okubo Y; Halldin C; Farde L
    Neuroimage; 1999 Feb; 9(2):235-42. PubMed ID: 9927552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No D2 receptor increase in PET study of schizophrenia.
    Farde L; Wiesel FA; Hall H; Halldin C; Stone-Elander S; Sedvall G
    Arch Gen Psychiatry; 1987 Jul; 44(7):671-2. PubMed ID: 2955770
    [No Abstract]   [Full Text] [Related]  

  • 19. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride.
    Farde L; Halldin C; Stone-Elander S; Sedvall G
    Psychopharmacology (Berl); 1987; 92(3):278-84. PubMed ID: 2957716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
    Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.